Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Voyager Therapeutics, Inc. VYGR

Healthcare  —  Biotechnology
2.68 (0.12) (4.29%) as of 25 Sep
Market cap
$172.5M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Voyager Therapeutics, Inc. (VYGR) Business Profile

Updated before January 2025

Company Overview

Voyager Therapeutics, Inc. (NASDAQ: VYGR) is a biotechnology company focused on developing life-changing gene therapies for severe neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, Voyager Therapeutics has established itself as a leader in the field of adeno-associated virus (AAV) vector engineering and gene therapy development. The company was co-founded by prominent scientists and entrepreneurs, including Dr. Mark Kay, Dr. Ben Shapiro, and Dr. Steven Paul, who have extensive expertise in neuroscience and gene therapy. Voyager’s leadership team is spearheaded by CEO Alfred W. Sandrock Jr., M.D., Ph.D., a seasoned executive with decades of experience in the biopharmaceutical industry.

Voyager’s mission is to harness the power of gene therapy to address the underlying causes of neurological diseases, offering hope to patients with limited treatment options. The company has built a robust pipeline of innovative therapies and established strategic partnerships with leading pharmaceutical companies to advance its research and development efforts.

Core Business Segments

Voyager Therapeutics operates primarily in the field of gene therapy, with a focus on developing treatments for neurological disorders. The company’s core business segments include:

1. Gene Therapy Pipeline

Voyager’s gene therapy pipeline is centered on the development of AAV-based therapies for severe neurological diseases. Key programs include:

  • Parkinson’s Disease: Voyager is developing gene therapies targeting alpha-synuclein, a protein implicated in the progression of Parkinson’s disease. The company’s lead candidate, VY-AADC, aims to enhance dopamine production in the brain.
  • Huntington’s Disease: Voyager is working on therapies to silence the mutant huntingtin gene, which causes Huntington’s disease.
  • ALS (Amyotrophic Lateral Sclerosis): The company is exploring gene therapies to address genetic mutations linked to ALS.

2. AAV Capsid Discovery Platform

Voyager has developed a proprietary AAV capsid discovery platform called TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA). This platform enables the identification of novel AAV capsids with improved tissue targeting, reduced immunogenicity, and enhanced therapeutic potential. The TRACER™ platform is a cornerstone of Voyager’s business, as it supports both internal programs and external collaborations.

3. Strategic Partnerships

Voyager collaborates with leading pharmaceutical companies to leverage its AAV technology and accelerate the development of gene therapies. Notable partnerships include agreements with Pfizer, Neurocrine Biosciences, and Novartis. These collaborations provide Voyager with funding, expertise, and access to broader markets.

Business Model

Voyager Therapeutics operates on a hybrid business model that combines in-house research and development with strategic partnerships. The company generates revenue through:

  • Licensing Agreements: Voyager licenses its AAV capsid technology and gene therapy programs to pharmaceutical partners in exchange for upfront payments, milestone payments, and royalties on future sales.
  • Collaborative Research: Voyager engages in joint research programs with partners, sharing resources and expertise to advance gene therapy development.
  • Internal Product Development: The company invests in its own pipeline of gene therapies, aiming to bring innovative treatments to market and capture long-term value.

This diversified approach allows Voyager to mitigate risks associated with drug development while maintaining a strong focus on innovation.

Strategic Direction

Voyager Therapeutics is committed to advancing its mission of transforming the treatment of neurological diseases through gene therapy. Key strategic priorities include:

  • Expanding the AAV Capsid Platform: Voyager aims to enhance its TRACER™ platform by discovering new capsids with improved therapeutic properties. This will enable the development of more effective and targeted gene therapies.
  • Advancing Clinical Programs: The company is focused on progressing its lead candidates, such as VY-AADC for Parkinson’s disease, through clinical trials and regulatory approval.
  • Exploring New Indications: Voyager is actively investigating additional neurological and non-neurological indications where gene therapy can have a transformative impact.
  • Sustainability Goals: While not a traditional focus for biotech companies, Voyager is exploring ways to integrate sustainable practices into its operations, including reducing waste and optimizing resource use in its research facilities.

Competitive Landscape

Voyager Therapeutics operates in a highly competitive and rapidly evolving field. Key competitors include:

  • Biogen: A leader in neuroscience, Biogen develops therapies for neurological diseases, including gene therapies.
  • Sangamo Therapeutics: Focused on genomic medicine, Sangamo develops gene therapies for neurological and other diseases.
  • uniQure: A pioneer in AAV-based gene therapies, uniQure has a strong pipeline targeting neurological and cardiovascular diseases.
  • Bluebird Bio: Known for its gene therapies targeting rare diseases, Bluebird Bio is a significant player in the gene therapy space.

Voyager differentiates itself through its proprietary TRACER™ platform and focus on neurological diseases, which positions it as a leader in the field.

Risk Factors

Like any biotechnology company, Voyager Therapeutics faces several risks, including:

  • Regulatory Challenges: The development and approval of gene therapies are subject to stringent regulatory requirements, which can delay or prevent product launches.
  • Market Dependence: Voyager relies heavily on its partnerships and licensing agreements for revenue, making it vulnerable to changes in partner priorities.
  • Supply Chain Disruptions: The production of AAV vectors requires specialized materials and processes, which can be affected by supply chain issues.
  • Competition: The gene therapy market is highly competitive, with numerous companies vying for market share.
  • Clinical Trial Risks: The success of Voyager’s pipeline depends on the outcomes of clinical trials, which are inherently uncertain.

Recent Developments

Voyager Therapeutics has made significant progress in recent years, including:

  • Advancements in TRACER™ Platform: The company has identified several novel AAV capsids with improved targeting capabilities, which are being integrated into its pipeline and partnerships.
  • New Partnerships: Voyager recently expanded its collaboration with Pfizer to include additional targets for gene therapy development.
  • Pipeline Progress: The company has reported positive preclinical data for its Huntington’s disease program and is preparing to initiate clinical trials.
  • Corporate Strategy: Voyager has streamlined its operations to focus on its core strengths, including AAV capsid discovery and neurological gene therapies.

Investment Considerations

Investors considering Voyager Therapeutics should weigh the following factors:

Strengths

  • Innovative Technology: Voyager’s TRACER™ platform is a key differentiator in the gene therapy market.
  • Strong Partnerships: Collaborations with leading pharmaceutical companies provide financial stability and access to resources.
  • Focused Pipeline: The company’s emphasis on neurological diseases addresses significant unmet medical needs.

Risks

  • Early-Stage Pipeline: Most of Voyager’s programs are in preclinical or early clinical stages, which carry higher risks.
  • Dependence on Partners: Revenue is heavily reliant on licensing agreements and collaborations.
  • Market Volatility: The biotechnology sector is subject to significant market fluctuations.

Conclusion

Voyager Therapeutics is a pioneering biotechnology company with a strong focus on gene therapy for neurological diseases. Its innovative TRACER™ platform and strategic partnerships position it as a leader in the field. While the company faces risks associated with early-stage development and market competition, its robust pipeline and commitment to innovation offer significant growth potential. As the demand for gene therapies continues to rise, Voyager is well-positioned to capitalize on emerging opportunities and deliver transformative treatments to patients worldwide.